論文 - 詳細
| RRC ID | 66241 |
|---|---|
| 著者 | Uemura K, Sasaki M, Sanaki T, Toba S, Takahashi Y, Orba Y, Hall WW, Maenaka K, Sawa H, Sato A. |
| タイトル | MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2. |
| ジャーナル | Sci Rep |
| Abstract |
Although the spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has resulted in a worldwide pandemic, there are currently no virus-specific drugs that are fully effective against SARS-CoV-2. Only a limited number of human-derived cells are capable of supporting SARS-CoV-2 replication and the infectivity of SARS-CoV-2 in these cells remains poor. In contrast, monkey-derived Vero cells are highly susceptibility to infection with SARS-CoV-2, although they are not suitable for the study of antiviral effects by small molecules due to their limited capacity to metabolize drugs compared to human-derived cells. In this study, our goal was to generate a virus-susceptible human cell line that would be useful for the identification and testing of candidate drugs. Towards this end, we stably transfected human lung-derived MRC5 cells with a lentiviral vector encoding angiotensin-converting enzyme 2 (ACE2), the cellular receptor for SARS-CoV-2. Our results revealed that SARS-CoV-2 replicates efficiently in MRC5/ACE2 cells. Furthermore, viral RNA replication and progeny virus production were significantly reduced in response to administration of the replication inhibitor, remdesivir, in MRC5/ACE2 cells compared with Vero cells. We conclude that the MRC5/ACE2 cells will be important in developing specific anti-viral therapeutics and will assist in vaccine development to combat SARS-CoV-2 infections. |
| 巻・号 | 11(1) |
| ページ | 5376 |
| 公開日 | 2021-3-8 |
| DOI | 10.1038/s41598-021-84882-7 |
| PII | 10.1038/s41598-021-84882-7 |
| PMID | 33686154 |
| PMC | PMC7940632 |
| MeSH | Angiotensin-Converting Enzyme 2 / metabolism* Animals Antiviral Agents / pharmacology* Antiviral Agents / therapeutic use COVID-19 Drug Treatment Cell Engineering* Cell Line Drug Discovery* Humans Models, Biological* SARS-CoV-2 / drug effects SARS-CoV-2 / physiology* Viral Proteins / biosynthesis Virus Replication / drug effects |
| IF | 3.998 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | X(Twitter) |
| 各媒体での言及数の合計 | 14 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | CACO-2(RCB0988) 293T(RCB2202) |